Division of Epigenomics AG
Latest From Epigenomics Inc.
Israel’s Check-Cap Ltd. is looking to increase compliance with colorectal cancer screening recommendations with its ingestible, X-ray-based, gastrointestinal imaging device. The Check-Cap Imaging Capsule is designed to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy, without a hospital visit or aggressive bowel preparation.
Regulatory Briefs: FDA Meetings On Cancer Tests, Glaucoma Devices; DeLauro Questions Device Reclassifications
An FDA advisory panel will discuss PMAs for two molecular diagnostics for colorectal cancer screening in March. A February workshop will address clinical trial design for minimally invasive glaucoma devices. Rep. DeLauro speaks out about FDA device reclassifications. More regulatory briefs.
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.
- In Vitro Diagnostics
- Therapeutic Areas
- ORCA BIOSCIENCES INC.
- North America
- Parent & Subsidiaries
- Epigenomics AG
- Senior Management
Noel Doheny, CEO
Gary Schweikhardt, Pres. & COO
- Contact Info
Phone: (206) 883-2900
1000 Seneca Street
P.O. Box 15259 Seattle, WA 98101
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.